ProShares Ultra Nasdaq Biotechnology
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 7501 Wisconsin Avenue, Suite 1000E Bethesda MD United States of America 20814
- IPO Date
- Apr 7, 2010
- CIK
- 0001174610
- Website
- proshares.com
- Similar Companies
- Business
- ProShares Ultra Nasdaq Biotechnology (BIB) seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index, a modified market-cap-weighted index measuring Nasdaq-listed biotechnology and pharmaceutical companies; it achieves this objective through investments in equity securities, derivatives such as total return swaps with counterparties including Citibank NA, BNP Paribas, Bank of America NA, Societe Generale, Goldman Sachs International, and UBS AG, U.S. Treasury obligations, and short-term investments. The fund offers leveraged exposure primarily to the health care sector, with top holdings including Vertex Pharmaceuticals Inc., Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., and Alnylam Pharmaceuticals Inc., alongside approximately 250 other biotechnology and pharmaceutical stocks. BIB targets investors seeking amplified daily returns from the biotechnology industry segment, with options trading available and quarterly distributions. Launched on April 7, 2010, and managed by ProShare Advisors LLC under the ProShares Trust, the ETF is domiciled in the United States with net assets of approximately $44.3 million as of May 31, 2025, a net expense ratio of 0.95%, and a portfolio turnover rate of 28%. In a significant operational change, after the close of business on November 13, 2024, the fund's broad-based securities market index for comparative performance purposes shifted from the Nasdaq-100 Index to the Nasdaq Composite Index to provide a broader benchmark.
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Cross Below 50 Day Moving Average – What’s Next?
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average – Here’s Why
BIB: A Tactical 2 X Leveraged Biotech ETF
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
Equity CEFs/ETFs: Top Picks For 2024 - Part II
The 7 Best ETFs to Buy to Cover 2023's Biggest Investing Opportunities
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Why Now Could Be The Time To Consider Neuroscience Investments
Top Performing Leveraged/Inverse ETFs: 08/07/2022
Cap-Weighting Crucial When Indexing Biotech
How to Invest in Biotech in 2022
Take a Look at the Top-Performing Biotech ETFs YTD
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval
As Covid Cases Mutate, the Biotech Industry Works to Keep Up
5 Best Leveraged ETFs of Last Week
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Bought by Capital Investment Advisors LLC
Tower Research Capital LLC TRC Sells 20,453 Shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)
The biotech sector as a safe bet for investments during the crisis